Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells

Oncogene. 2001 May 3;20(20):2499-513. doi: 10.1038/sj.onc.1204349.


Constitutive activation of signal transducer and activator of transcription (STAT) proteins has been detected in a wide variety of human primary tumor specimens and tumor cell lines including blood malignancies, head and neck cancer, and breast cancer. We have previously demonstrated a high frequency of Stat3 DNA-binding activity that is constitutively-induced by an unknown mechanism in human breast cancer cell lines possessing elevated EGF receptor (EGF-R) and c-Src kinase activities. Using tyrosine kinase selective inhibitors, we show here that Src and JAK family tyrosine kinases cooperate to mediate constitutive Stat3 activation in the absence of EGF stimulation in model human breast cancer cell lines. Inhibition of Src or JAKs results in dose-dependent suppression of Stat3 DNA-binding activity, which is accompanied by growth inhibition and induction of programmed cell death. In addition, transfection of a dominant-negative form of Stat3 leads to growth inhibition involving apoptosis of breast cancer cells. These results indicate that the biological effects of the Src and JAK tyrosine kinase inhibitors are at least partially mediated by blocking Stat3 signaling. While EGF-R kinase activity is not required for constitutive Stat3 activation in breast cancer cells, EGF stimulation further increases STAT DNA-binding activity, consistent with an important role for EGF-R in STAT signaling and malignant progression. Analysis of primary breast tumor specimens from patients with advanced disease revealed that the majority exhibit elevated STAT DNA-binding activity compared to adjacent non-tumor tissues. Our findings, taken together, suggest that tyrosine kinases transduce signals through Stat3 protein that contribute to the growth and survival of human breast cancer cells in culture and potentially in vivo.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Breast Neoplasms / enzymology
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / pathology*
  • Cell Cycle / drug effects
  • Cell Division / physiology
  • DNA, Neoplasm / metabolism
  • DNA-Binding Proteins / metabolism
  • DNA-Binding Proteins / physiology*
  • Drosophila Proteins*
  • Enzyme Inhibitors / pharmacology
  • ErbB Receptors / biosynthesis
  • ErbB Receptors / physiology
  • Fibroblasts / enzymology
  • Fibroblasts / metabolism
  • Fibroblasts / physiology
  • Humans
  • Insect Proteins
  • Janus Kinase 1
  • Mice
  • Phosphorylation / drug effects
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Protein-Tyrosine Kinases / metabolism
  • Protein-Tyrosine Kinases / physiology*
  • Pyridones / pharmacology
  • Pyrimidines / pharmacology
  • STAT3 Transcription Factor
  • Signal Transduction / physiology
  • Trans-Activators / metabolism
  • Trans-Activators / physiology*
  • Tumor Cells, Cultured
  • Tyrphostins / pharmacology
  • src-Family Kinases / antagonists & inhibitors
  • src-Family Kinases / metabolism
  • src-Family Kinases / physiology*


  • DNA, Neoplasm
  • DNA-Binding Proteins
  • Drosophila Proteins
  • Enzyme Inhibitors
  • Insect Proteins
  • Pyridones
  • Pyrimidines
  • STAT3 Transcription Factor
  • STAT3 protein, human
  • Stat3 protein, mouse
  • Trans-Activators
  • Tyrphostins
  • alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide
  • janA protein, Drosophila
  • ErbB Receptors
  • Protein-Tyrosine Kinases
  • JAK1 protein, human
  • Jak1 protein, mouse
  • Janus Kinase 1
  • src-Family Kinases
  • PD 180970